Disc Medicine, Inc.
StreetZero Signal 60
About Disc Medicine, Inc.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. The company is building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. It is headquartered in Watertown, Massachusetts.
LATEST FUNDINGRule 144
$550K
Announced 2026-10-20
TOTAL RAISED$140M
IN THE NEWS
- 🔗 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants - Disc Medicine Inc.
- 🔗 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
- 🔗 Disc Medicine - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Disc Medicine proposes $350M public offering | IRON Stock News
- 🔗 With 52% ownership, Disc Medicine Opco Inc (NASDAQ:IRON) boasts of strong institutional backing
EMPLOYEES—
FOUNDED2017
HQWatertown, MA, United States
Industry
Public Equity (Nasdaq)
Tags
BiopharmaceuticalClinical-stageHematologic diseasesPublic
Key highlights
- Clinical-stage company focused on heme biosynthesis and iron homeostasis pathways for blood disorders.
- Completed upsized $259.3M public offering and announced proposed $350M follow-on offering.
- Raised $140M total across four rounds with backing from 14 institutional investors.
- Strong institutional ownership at 52% of shares outstanding.
Ask StreetZero about Disc Medicine, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (Nasdaq) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account